LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
LENZ Therapeutics reported Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ product sales, driven by approximately 25,000 paid prescriptions. The company has seen broad uptake by over 10,000 unique prescribers, with approximately 60% prescribing multiple times, and is expanding its sales force to 117 territories by the end of Q2 2026. LENZ launched a direct-to-consumer (DTC) campaign featuring Sarah Jessica Parker, which has driven strong initial consumer engagement, with website traffic increasing up to 10x following national media activations.
Key figures
- Eps Beat
- 0
- Revenue
- 1901000
- Revenue Yoy
- 0
- Net loss
- 41488000
- Prescribers
- 10000
- R d expenses
- 0
- Sga expenses
- 44960000
- Cash position
- 258400000
- Prescriptions
- 46000
- Product sales
- 1651000
- License revenue
- 250000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.